Hydroxychloroquine, Azithromycine and Zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19
Phase 3
- Conditions
- Respiratory
- Registration Number
- PACTR202005622389003
- Lead Sponsor
- Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 384
Inclusion Criteria
(i) patients above the age of 18 with PCR confirmed covid19 infection less than 72 hours prior to randomisation,;
(ii) absence danger signs such as respiratory distress requiring mechanical ventilation or supplemental oxygen encephalitic disorders, renal function failure;
(iii) absence of known chronic illness.
Exclusion Criteria
(i) Known allergy to any of the study medication;
(ii) pregnancy or breastfeeding;
(iii) ECG abnormality at admission;
(iii) Patients with ALAT/ASAT higher than 3 times the upper limit of normal on admission;
(iv) Patients with known chronic kidney diseases;
(v) Patients with known retinal diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with undetectable viral load 7 days after treatment initiation.
- Secondary Outcome Measures
Name Time Method Time to first PCR negative after treatment initiation. ;Absolute and relative changes in biochemical parameters from baseline to day 7 after treatment initiation. <br>Absolute and relative changes in haematological parameters from baseline to day 7 after treatment initiation. <br>Proportion of participants with ECG abnormality after treatment initiation<br>